Last reviewed · How we verify

NCT05506306: VERTEXO

Multitissular Effect of Vertical Mobilization Using the Exoskeleton AtalanteTM in Neurological Chair- or Bed-bound Patients

Status unknown Last updated 18 August 2022
What this trial tests

trial testing Assessment in Neurologic Disorder in 30 participants. Status unknown.

Timeline
1 September 2022
Primary endpoint
1 September 2023
1 September 2024

Quick facts

Lead sponsorHenri Mondor University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment30
Start date1 September 2022
Primary completion1 September 2023
Estimated completion1 September 2024

Drugs / interventions tested

Conditions studied

Sponsor

Henri Mondor University Hospital

Who can join

18 and older, any sex, with Neurologic Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background and aim: Sustained bed rest impairs many bodily functions. Verticalization restores gravitational challenge and the use of several organs. The Atalante™ exoskeleton (Wandercraft) is the only self-balanced exoskeleton, which allows walking without canes. We assessed multi-tissular effects of mobile reverticalization using Atalante™ in neurological bed- or wheelchair-bound patients. Methods: Observational cohort study. Inclusion criteria: bed- or wheelchair-bound for \>2 weeks and \<1 hour per day of stance, due to a central neurological disorder. Sessions with exoskeleton were 3/week, integrated in routine care. Data collected at baseline and after eight weeks (W8) included: cardiovascular (echocardiography, EKG, blood pressure lying and standing), pulmonary (spirometry), bone (densitometry, biochemical markers), bowels (daily stool frequency, Bristol Stool Scale), urinary (urinary flow, postmictional residual volume, urinary symptom profile questionnaire, USP), cognitive (trail making test, TMT-B), anxiety and depression (HAD), and quality of life (SF12). Results will be presented at the end of the study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Safety and efficacy of the Atalante exoskeleton in the rehabilitation of French patients with amyotrophic lateral sclerosis: a prospective, monocentric, open, uncontrolled, interventional protocol, EXALS.
    Trad G, Lenglet T, Ledoux I, Querin G, et al · · 2026 · PMID 41545051 · DOI 10.1136/bmjopen-2025-109620

Verify or expand the search:

Other trials of Assessment

Trials testing the same drug.

Other recruiting trials for Neurologic Disorder

Currently open trials in the same condition.

Other Henri Mondor University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05506306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing